Pfizer’s Selzentry Wins FDA Approval For HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.